Oncopeptides AB (SE0009414576) — research page
SE · se-cm-kg/XSTO/SE0009414576 · as of 2026-11-06
Identity and listing
The issuer is Oncopeptides AB, listed on Nasdaq Stockholm under the ticker SE0009414576, with ISIN SE0009414576 and LEI 549300J9WWQ5CBYQ1M77. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | Oncopeptides AB | source · 2026-11-06 |
| exchange | Nasdaq Stockholm | source · 2026-11-06 |
| ticker | SE0009414576 | source · 2026-11-06 |
| ISIN | SE0009414576 | source · 2026-11-06 |
| LEI | 549300J9WWQ5CBYQ1M77 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 43 filings in the window 2025-11-06 to 2026-11-06, on 39 filing days. The median gap between filing days is 5.5 days. The latest filing is dated 2026-11-05 and is an Interim report (Q1 and Q3), 1 day before the record date of 2026-11-06. The exchange median cadence gap is 9.5 days across 398 issuers, and the exchange median filings count is 30.0. The exchange median latency is 7.0 days. The sector median is not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 43 | 5.5 | 1 |
| exchange median: Nasdaq Stockholm (398 issuers) | 30 | 9.5 | 7 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-05 | Interim report (Q1 and Q3) | Interim report (Q1 and Q3) | Oncopeptides publishes Q3 report 2026 |
| 2026-11-04 | Investor News | Investor News | New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026 |
| 2026-10-30 | Total number of voting rights and capital | Total number of voting rights and capital | Number of shares and votes in Oncopeptides |
| 2026-10-29 | Investor News | Investor News | Invitation to presentation of the Q3 report 2026 |
| 2026-10-13 | Inside information | Inside information | Oncopeptides intends to carry out a directed share issue of approximately SEK 100 million |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor, its location and any auditor changes are not on the record, as this register has no lifecycle type map yet.
Events and halts
The listing, delisting, name change, domicile change and segment move lines are not on the record, as this register has no lifecycle type map yet. The halt flag shows listed, not halted.
Orderability
The outcome is not determinable under acm-68000/se/mifid-ii-product-governance/r1, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The chapter is as of 2026-11-04.
rule acm-68000/se/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 3 research houses: ABG Sundal Collier, DNB Carnegie and Redeye.
| research house | analyst | source · read date |
|---|---|---|
| ABG Sundal Collier | Georg Tigalonov-Bjerke | issuer page · 2026-11-12 |
| DNB Carnegie | Erik Hultgård | issuer page · 2026-11-12 |
| Redeye | Richard Ramanius | issuer page · 2026-11-12 |
Open research
No openly published research notes were found on the record.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.
Sources
7 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.se-cm-kg.ai/events/XSTO/SE0009414576 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)
- 10.5
- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://oncopeptides.com/investors/the-share/ (coverage)
- 10.7
- https://mcp.se-cm-kg.ai/record/XSTO/SE0009414576 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"SE0009414576"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:5b8f211735361730.